Regarding the Covishield vaccine and its uncommon adverse effects. A significant update has surfaced and is raising concerns among a number of medical professionals. The British-Swedish multinational biotechnology and pharmaceutical corporation AstraZeneca has acknowledged in court documents that uncommon side effects are possible with its COVID-19 vaccine, Covishield, according to The Telegraph.
AstraZeneca created Covishield, which the Serum Institute of India manufactured. It was one of the COVID vaccines that was frequently given in India.
For the first time, the massive British pharmaceutical company AstraZeneca has acknowledged that the Covid vaccination may cause an uncommon blood clotting disorder. The acknowledgment appears in a court document that is part of a class action lawsuit that families have filed, claiming the vaccine has harmed them.
AstraZeneca talked about the covishield cause and side-effects
AstraZeneca is currently dealing with a class action lawsuit in the UK because of allegations that their vaccine resulted in fatalities. AstraZeneca has been the target of 51 lawsuits. AstraZeneca acknowledged that Covishield may “in very rare cases, cause TTS” in one of the court documents. Thrombosis with Thrombocytopenia Syndrome is referred to as TTS. A rare but dangerous illness known as thrombosis with thrombocytopenia syndrome (TTS) is characterized by low platelet counts (thrombocytopenia) and blood clot formation (thrombosis).
The symptoms of TTS usually include excruciating headaches, stomach pain, leg swelling, dyspnea, and neurological impairments. Blood tests to measure platelet counts and imaging examinations to find blood clots are part of the diagnosis process. TTS patients are continuously watched by medical professionals because there is a risk of serious complications, such as organ damage and death. For those suffering from this uncommon but serious illness, prompt identification and treatment are crucial to improve their prognosis.
Danger signs you shouldn’t get ignore of side-effect
The drug TTS : AstraZeneca, the maker of the COVID-19 vaccine that is extensively used in India, has disclosed the possibility of TTS adverse effects. Thrombosis with Thrombocytopenia Syndrome (TTS) is an uncommon but dangerous condition characterized by low platelet counts and blood clots. Headaches, impaired vision, and chest pain are some of the symptoms. Dr. Jayadevan places a strong emphasis on awareness and early intervention for successful management. The admission by AstraZeneca comes after adenovirus vector vaccinations were connected to cases of TTS.
Even though TTS is uncommon, people who have had vaccinations linked to it should watch out for symptoms and get help right away if they appear within a few weeks of the shot. Effective management of TTS requires early detection and intervention. TTS was identified by the World Health Organization (WHO) in 2023 as a new adverse event that occurred after vaccination in people who received COVID-19 non-replicant adenovirus vector-based vaccines, such as the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccine and the AstraZeneca COVID-19 ChAdOx-1 vaccine.
Covid vaccine, Covishield may cause blood clotting: Should you be worried?
Zeneca’s disclosure of the uncommon adverse event brought on by their Covid-19 vaccination. The National Indian Medical Association’s co-chairman, Dr. Rajeev Jayadevan, noted that this specific result is only documented in the first month after the initial dosage, not later. According to Dr. Kumar, it is unknown how frequently TTS occurs in India following vaccination.
As of last week, less than 40 incidents of blood clots had been documented in the UK and the EU out of the more than 17 million people who have gotten the vaccination. The expert stated that these discoveries are not new. Since 2021, there have really been rare case reports of TTS from all around the world following Covid-19 vaccines.
